Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 671 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection February 7, 2025 Sotorasib in Combination with Panitumumab Results in Longer PFS in Patients... December 6, 2023 Apalutamide Plus ADT Provides Significant Improvement in Overal Survival and Delays... May 6, 2021 Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... July 17, 2019 Load more HOT NEWS Coming Soon: Medicare Drug Price Negotiations What to Know About Using Activated Charcoal During Cancer What’s happened to cancer clinical trials during the COVID-19 pandemic? Dog Showers His Mom with Snuggles and Makes Her Laugh During...
